"1 - It must not be eliminated by a better drug/s. (Considering the marginal benefit of Copaxone, they could be displaced completely.)"
I might make the case for disagreeing with #1: As long as the drug has some utility, it will garner sales. The sales trajectory for now continues, which implies that the value of "some utility" will also rise.
A bad example might be aspirin being supplanted by Tylenol, Motrin, Aleve, etc. This doesn't even allude to the new uses that were found for aspirin, such as anti-platelet activity.
Perhaps Copaxone will be used elsewhere in addition to it's current indication.
As to #2, we can all agree; however, don't forget that management clearly alluded to additional FoB partnership's.
"<A – Richard Shea>: Yes, well, we did talk about the M118 program and the potential for partnering that program. And then we have also talked about follow-on biologics as an area that other than the two products that we are partnering with Sandoz, we have opportunities on that field too."
M118 partnering: The following quotes from last week by Craig Wheeler really struck me:
"...I couldn't be more pleased."
Stated that the M118 molecule is behaving (verbatim) "exactly as we hoped it would behave."
Market Data 
Markets 
AI
